Comparative Pharmacology
Head-to-head clinical analysis: ACTONEL versus ATELVIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTONEL versus ATELVIA.
ACTONEL vs ATELVIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and interfering with osteoclast activity.
Risedronate (the active ingredient in ATELVIA) inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting the mevalonate pathway, which prevents farnesyl pyrophosphate synthase activity, leading to disruption of osteoclast function and induction of apoptosis.
35 mg orally once weekly or 5 mg orally once daily for osteoporosis; also 30 mg orally once weekly for Paget disease.
35 mg orally once weekly on the same day each week, taken with at least 240 mL of plain water at least 30 minutes before the first food, beverage, or medication of the day. Do not crush, chew, or suck tablets.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (short for bisphosphonates due to rapid renal clearance); however, bone retention half-life is prolonged (>1 year) due to binding to hydroxyapatite.
Terminal elimination half-life is approximately 10 days due to prolonged bone binding and slow release; clinical suppression of bone resorption persists for weeks after discontinuation.
Renal: 50-60% unchanged via glomerular filtration and active tubular secretion; Fecal: minor, biliary excretion negligible.
Approximately 50% of absorbed dose excreted renally unchanged; remainder eliminated via biliary/fecal routes. Renal clearance correlates with creatinine clearance.
Category C
Category C
Bisphosphonate
Bisphosphonate